(Stroke. 2000;31:3029.)
© 2000 American Heart Association, Inc.
Original Contributions |
From the Departments of Radiology, Division of Interventional Neurovascular Radiology (A.M.M., R.T.H., C.C.P., T.E.L., P.M.M., C.F.D., V.V.H.), Neurology (W.S.S.), and Neurosurgery (R.T.H., C.F.D., V.V.H.), University of California at San Francisco.
Correspondence to Adel M. Malek, MD, PhD, Department of Neurosurgery, Brigham & Womens and Childrens Hospitals, Bader 3, 300 Longwood Ave, Boston, MA 02115. E-mail amalek{at}partners.org
| Abstract |
|---|
|
|
|---|
MethodsTwenty-eight consecutive symptomatic NASCET-ineligible patients (10 female; median age, 72.2 years) underwent microcatheter-based carotid stent angioplasty. Half of the patients had sustained a previous stroke. Classification of surgical risk by Sundt criteria yielded no patients in grade 1, 3 patients in grade 2 (10.7%), 8 in grade 3 (28.6%), and 17 (60.7%) in grade 4. Stratification of stroke risk for medical therapy according to the European Carotid Surgery Trial (ECST) 5-point score showed 8 patients with a score of 3 (28.6%), 12 with 4 (42.8%), and 8 with 5 (28.6%). Follow-up was obtained in all patients at a median of 14 months.
ResultsThe procedure was technically successful in all cases (100%), with immediate stenosis reduction from a mean of 80.3% to 2.7%. There were no periprocedural deaths, 1 major stroke (3.6%), no minor strokes, and 3 transient ischemic attacks (10.7%). In-hospital complications included 2 nonfatal myocardial infarctions, 1 case of acute renal failure, and 1 groin hematoma requiring transfusion. There were 5 deaths during the follow-up period, all beyond 30 days after the procedure: 3 from cardiac causes, 1 from lung cancer, and 1 following unrelated surgery. The patient with major stroke died at 7.8 months during rehabilitation. No surviving patients had further strokes, and all except 1 (95.5%) remained asymptomatic. Anatomic follow-up in 20 patients showed occlusion in 2 (10%) (1 symptomatic, 1 asymptomatic) and intimal hyperplasia in 3 asymptomatic patients (15%).
ConclusionsThe clinical results and sustained freedom from symptoms and stroke during the short available follow-up period suggest that stent angioplasty may be useful in the treatment of symptomatic cervical carotid stenosis in high-risk patients despite a notable incidence of restenosis.
Key Words: angioplasty carotid endarterectomy carotid stenosis endovascular therapy stents
| Introduction |
|---|
|
|
|---|
| Subjects and Methods |
|---|
|
|
|---|
Procedure
Twenty-four patients (86%) underwent light
intravenous neuroleptic sedation, and the remainder had
general endotracheal anesthesia (n=4, 14%) because of poor
ability to cooperate (n=2) or because of the need for intracranial
navigation (n=2). All patients were monitored by placement of
transthoracic electrodes (Zoll Medical) in case of
bradycardia or asystole during angioplasty. Patients were administered
intravenous heparin (bolus of 70 U/kg) followed by either
an hourly dose (bolus of 35 U/kg) or continuous infusion (15 U/kg per
hour) to ensure an activated clotting time greater than twice
baseline. After a complete diagnostic angiographic study,
the stenotic lesion was treated with an angioplasty balloon
catheter (predilatation) to enable subsequent passage of a
balloon-mounted (Palmaz, Johnson & Johnson; GFX, AVE/Medtronic) or
self-expanding stent (Wallstent, Schneider; S.M.A.R.T. stent, Cordis).
In 7 cases (25%), primary stenting was performed without resorting to
predilatation. Postdeployment high-pressure balloon angioplasty (12 to
21 atm) was then performed to achieve apposition of the stent
interstices to the luminal surface of the artery. The patient was
maintained on heparin for 12 hours and placed on an oral regimen of
ticlopidine (250 mg PO BID) or clopidogrel (75 mg PO QD) for 6 weeks
and on daily aspirin (325 mg PO QD) indefinitely.
Risk Stratification
Patients were classified according to the Sundt grading system
on the basis of angiographic, medical, and neurological risk
factors5 and grouped according to risk of stroke with
medical treatment as validated in the ECST7 on the basis
of cerebral versus ocular symptoms, plaque surface irregularity,
neurological event in past 2 months, and percentage of
stenosis.
Clinical Outcome Measures
Members of the neurology department performed initial inpatient
neurological examinations and clinical management, with initial
postprocedural care in a neurological intensive care setting. Follow-up
neurological examinations and ultrasonography were performed by the
neurology team or at the patients referring institution and were
supplemented by telephone interviews with a clinical nurse.
Quantitative Analysis and Statistics
Severity of stenosis was computed by the NASCET method
with interconversion to ECST values as previously
described.13 Statistical analysis was performed
with software from SAS Institute. ANOVA was used to compare outcome
scores versus presentation and treatment characteristics,
and a Pearsons
2 test was used to determine
marginal homogeneity among nominal variables. A P value
of 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
Lesion Characteristics and Technique
Half of the lesions were left sided (14/28 patients, 50%). The
mean pretreatment stenosis of 80.3±2.8% was immediately
reduced to 2.7±1.2% by the procedure (P<0.001). The
morphological characteristics of the plaque included presence of an
ulcerated or irregular plaque in 15 patients (15/28 patients, 53.6%),
tandem lesions in 9 patients (9/28 patients, 32.1%), and evidence of a
string sign in 6 patients (6/28 patients, 21.4%). Fifteen patients
(15/28 patients, 53.6%) had >50% stenosis in the
contralateral internal carotid artery, and among these 9 (9/28
patients, 32.1%) had complete occlusion. Mean stenosis in the
contralateral cervical internal carotid artery was 50.5±7.6%. Ten
patients (10/28 patients, 35.7%) demonstrated extracranial posterior
circulation atherosclerotic disease of >60%, and 9 (9/28 patients,
32.1%) had moderate to severe intracranial atherosclerotic disease as
defined by Kappelle et al.14
To achieve an adequately smooth hemodynamic result, tandem stents were placed in 7 patients (7/28 patients, 25%) with overlap of 2 or 3 stents in 4 patients (4/28 patients, 14.3%). A total of 34 stents were used, including self-expanding Wallstent (n=24) and S.M.A.R.T. (n=2) stents and balloon-mounted Palmaz (n=6) and GFX (n=2) stents. Eight patients (8/28 patients, 28.6%) underwent combined simultaneous endovascular procedures either at the time of stent angioplasty or during the same hospital admission. These complex procedures included unsupported and stent-supported angioplasty of the intracranial portion of the internal carotid artery (n=4), of the vertebral artery (n=2), of the left proximal common carotid artery (n=1), and of the contralateral cervical internal carotid artery (n=1).
Complications
There were no perioperative deaths in this series.
There was 1 major stroke event (1/28 patients, 3.6%) in a 78-year-old
man (Sundt grade 4/ECST score 3) with previous stroke and progressively
worsening neurological condition. The patient had poor angiographic
hemodynamic reserve with an ulcerated left internal
carotid artery lesion of 75% stenosis, contralateral carotid
and right vertebral artery occlusion, and significant stenosis
of the left vertebral artery. The procedure, performed under general
endotracheal anesthesia because of poor cooperation, was
characterized by a period of prolonged uncontrolled hypotension before
endovascular intervention. The patient awoke with left-sided
hemiparesis, and postprocedural imaging revealed infarction in the
regions of the right basal ganglia and corona radiata,
consistent with a hypoperfusion insult. There were no instances
of minor stroke (0%) and 3 transient ischemic attack (TIA)
episodes (3/28, 10.7%). The TIAs were encountered in patients
belonging to each of Sundt grades 2, 3, and 4 and to each of the ECST
score 3, 4, and 5 subgroups. No significant relationship between
stroke/TIA event rate and Sundt grade or ECST score was found. Complex
procedures (8/28 patients, 28.6%) were not associated with a higher
risk of stroke (0 stroke) or TIA (1 TIA) compared with noncomplex
procedures (20/28 patients, 71.4%). Primary stenting (7/28 patients,
25%) was associated with 1 TIA and 1 major stroke, while secondary
stenting (after primary balloon angioplasty) (21/28 patients, 75%) was
associated with 2 TIAs and no stroke.
The immediate postoperative hospital course was complicated by a groin hematoma in 1 patient (1/28 patients, 3.6%) that required blood transfusion and ultrasound-guided external compression. Two patients had postprocedural non-Q-wave myocardial infarctions (2/28 patients, 7.1%), from which they recovered before discharge, and 1 patient suffered from acute renal failure (1/28, patients, 3.6%) with only partial recovery.
Clinical Follow-Up
Clinical follow-up was obtained in all patients, with a median
duration of 14 months (range, 0.8 to 26.7 months). During the follow-up
period, there was 1 death in the patient who had the
perioperative major stroke from complications related
to his long-term rehabilitation at 7.8 months and 5 deaths that were
unrelated to the treatment. The latter included 3 cardiac deaths (1
from fatal myocardial infarction at 4.4 months, 1 from cardiac arrest
at 4.6 months, and 1 from intractable congestive heart failure at 13.3
months); 1 death from small-cell lung cancer (0.8 months); and 1
postoperative death after hip surgery (14 months). The patient who had
cardiac arrest at 4.6 months was 1 of the 2 patients who had sustained
a postprocedural myocardial infarction. Overall, 24 patients (85.7%)
had clinical follow-up of duration >6 months; of the 4 who did not, 3
were the result of death as described above. Seventeen patients had
clinical follow-up at >1 year.
Of the surviving 22 patients, 21 (21/22 patients, 95.5%) remained free of new symptoms or new strokes, while 1 patient (1/22 patients, 4.5%) who underwent simultaneous treatment of an intracranial internal carotid artery stenosis and a cervical carotid lesion developed delayed central retinal artery occlusion and ipsilateral ocular blindness at 2 months. Subsequent angiography revealed occlusion of the carotid artery at the siphon with proximal cervical carotid flow stasis at the level of the stented segment.
Anatomic follow-up was available at >6 months after the procedure and consisted of either ultrasonography or conventional angiography in 20 of the 28 patients (20/28 patients, 71%). Three asymptomatic patients (Sundt grade 3/ECST score 4 in 2; Sundt grade 4/ECST score 5 in 1) developed >60% intimal hyperplasia, 2 of which (65% and 80% restenosis) were treated successfully with further angioplasty and reconstitution of patency. Two patients, one symptomatic from occlusion of the ipsilateral central retinal artery (Sundt grade 4/ECST score 5) and another asymptomatic (Sundt grade 3/ECST score 4), showed complete occlusion at follow-up. Neither underwent recanalization attempts because of the irreversible deficit in the first and the absence of related symptoms in the other. Pretreatment stenosis in the patients who subsequently had restenosis or occlusion (87.8%, n=5) was not significantly different from those who did not (79.5%, n=15) (P<0.23).
| Discussion |
|---|
|
|
|---|
The decision to treat carotid stenosis relies on a cost-benefit
analysis that takes into account the cumulative risk of stroke
in a patient undergoing medical treatment and the procedure-related
risks of stroke and death from surgical or endovascular
revascularization. Analysis of multiple
published endarterectomy studies by Rothwell et
al17 has identified a significantly higher combined risk
of stroke and death in symptomatic (5.18%) than in
asymptomatic (3.35%) patients, a finding confirmed by
McCrory et al18 (9.5% in symptomatic versus
2.7% in asymptomatic patients). This difference may be the
result of a higher rate of embolic events, as suggested by the greater
frequency of high-intensity transient signals seen in
symptomatic patients.19 Recent
analysis of the NASCET surgical results has identified a
greater perioperative risk in patients with hemispheric
versus retinal symptoms (2.3-fold), contralateral carotid occlusion
(2.2-fold), a left-sided procedure (2.3-fold), or an
irregular/ulcerated lesion (1.5-fold).3 A similar effect
of hemispheric symptoms and plaque ulceration has also been reported in
ECST.7 In addition, available data to guide treatment in
high-risk patients who fail to qualify by NASCET criteria are scarce.
The predictive value of Sundts grading system, initially based on
retrospective analysis at a single center,5 has
been independently validated both retrospectively18 20 and
prospectively in a study from the Academic Medical Center
Consortium.18 Sieber et al20 found that total
morbidity and mortality from CEA increased from 2% for Sundt grade 1
to 10% for grade 2, 11% for grade 3, and 18% for grade 4. McCrory et
al18 reported total stroke or death rates of 2.5% for
grade 1, 3.1% for grade 2, 5.1% for grade 3, and 7.9% for grade 4.
Although it is impossible to predict the risk of surgical therapy for
the patients in the present study, its computation based on the
Sundt instrument yields a rate of procedure-related death and stroke
rate ranging from 7.4%5 to 15.1%,20 which
is higher than observed in this report (3.6%). Applying the ECST
medical risk score and associated actuarial stroke rate (Table 3
) to the patient population in the present study yields a
predicted 5-year risk of ipsilateral stroke of 36.3%; however, direct
comparison will not be possible until longer follow-up is
available.
Even though the present series consists exclusively of symptomatic NASCET-ineligible patients with a high proportion of Sundt grade 3 and 4, the 30-day periprocedural combined risk of stroke and death (3.6%) is comparable to the surgical results of NASCET3 and other series.6 20 The risk of all in-hospital medical complications (including TIA) in this series was 25% (7/28 patients; 2 nonfatal myocardial infarction, 1 acute renal failure, 1 groin hematoma, 3 TIAs), which is higher than that encountered in NASCET (1% for myocardial infarction, 8.1% total medical complications excluding TIAs).21 The rate of wound-related complications (1 groin hematoma, 2.6%) is lower than in NASCET (9.3%), and no instances of perioperative cranial nerve injury were encountered (8.9% in NASCET).3 Although the majority (95.4%) of patients remained asymptomatic in the follow-up period, the risk of >60% restenosis or occlusion in the present study (5/20 patients, 25%) is higher than reported for the 3 to 18 months of follow-up of the 645 patients in the surgical arm of the Asymptomatic Carotid Atherosclerosis Study (ACAS) (7.6% to 11.4%)22 and greater than the 6- to 12-month rate reported in other series (8%).23 Since the original goal of the procedure was stroke prevention, the current management was effective in 4 of the 5 patients with >60% restenosis or occlusion for the limited length of follow-up. However, even if one were to consider only restenosis of >80% as clinically warranting retreatment, the rate in the present study remains significant at 15% (3/20 patients).
In conclusion, carotid stent angioplasty can be performed in NASCET-ineligible high-risk symptomatic patients with a periprocedural risk of stroke and death that is comparable to those of NASCET and other published endarterectomy series. A significant relief from neurological symptoms and stroke was encountered during the intermediate follow-up period along with significant restenosis in this cohort of patients with advanced medical and surgical risk factors.
| Acknowledgments |
|---|
Received May 11, 2000; revision received August 24, 2000; accepted August 24, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Groschel, U. Ernemann, J. B. Schulz, T. Nagele, C. Terborg, and A. Kastrup Statin Therapy at Carotid Angioplasty and Stent Placement: Effect on Procedure-related Stroke, Myocardial Infarction, and Death. Radiology, July 1, 2006; 240(1): 145 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Orbach, B. K. Pramanik, J. Lee, T. S. Maldonado, T. Riles, and R. I. Grossman Carotid Artery Stent Implantation: Evaluation with Multi-Detector Row CT Angiography and Virtual Angioscopy--Initial Experience Radiology, January 1, 2006; 238(1): 309 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. G. Roh, H. S. Byun, J. W. Ryoo, D. G. Na, W.-J. Moon, B. B. Lee, and D.-I. Kim Prospective Analysis of Cerebral Infarction After Carotid Endarterectomy and Carotid Artery Stent Placement by Using Diffusion-Weighted Imaging AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 376 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kaku, S.-i. Yoshimura, and J. Kokuzawa Factors Predictive of Cerebral Hyperperfusion after Carotid Angioplasty and Stent Placement AJNR Am. J. Neuroradiol., September 1, 2004; 25(8): 1403 - 1408. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Higashida, P. M. Meyers, C. C. Phatouros, J. J. Connors III, J. D. Barr, D. Sacks, and for the Technology Assessment Committees of the Am Reporting Standards for Carotid Artery Angioplasty and Stent Placement Stroke, May 1, 2004; 35(5): e112 - e134. [Full Text] [PDF] |
||||
![]() |
I. Linfante, J. A. Hirsch, M. Selim, G. Schlaug, L. R. Caplan, and A. S. Reddy Safety of Latest-Generation Self-expanding Stents in Patients With NASCET-Ineligible Severe Symptomatic Extracranial Internal Carotid Artery Stenosis Arch Neurol, January 1, 2004; 61(1): 39 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Barr, J. J. Connors III, D. Sacks, J. C. Wojak, G. J. Becker, J. F. Cardella, B. Chopko, J. E. Dion, A. J. Fox, R. T. Higashida, et al. Quality Improvement Guidelines for the Performance of Cervical Carotid Angioplasty and Stent Placement: Developed by a Collaborative Panel of the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, and the Society of Interventional Radiology AJNR Am. J. Neuroradiol., November 1, 2003; 24(10): 2020 - 2034. [Full Text] [PDF] |
||||
![]() |
K. Yoshida, K. Nozaki, K.-i. Kikuta, A. Sadato, S. Miyamoto, and N. Hashimoto Contrast-Enhanced Carotid Color-Coded Duplex Sonography for Carotid Stenting Follow-Up Assessment AJNR Am. J. Neuroradiol., May 1, 2003; 24(5): 992 - 995. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ballotta, G. D. Giau, C. Baracchini, C. P. Derdeyn, D. Fox, C. J. Moran, D. T. Cross III, and R. G. Dacey Jr Carotid Angioplasty and Stenting in High-Risk Patients With Severe Symptomatic Carotid Stenosis Stroke, April 1, 2003; 34(4): 834 - 835. [Full Text] [PDF] |
||||
![]() |
S. Taylor, F. Alcocer, and W. D. Jordan Jr Controversies in Carotid Stenting Vascular and Endovascular Surgery, March 1, 2003; 37(2): 79 - 87. [Abstract] [PDF] |
||||
![]() |
A. Kastrup, K. Groschel, H. Krapf, B. R. Brehm, J. Dichgans, and J. B. Schulz Early Outcome of Carotid Angioplasty and Stenting With and Without Cerebral Protection Devices: A Systematic Review of the Literature Stroke, March 1, 2003; 34(3): 813 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Fox Jr, C. J. Moran, D. T. Cross III, R. L. Grubb Jr, K. M. Rich, M. R. Chicoine, R. G. Dacey Jr, and C. P. Derdeyn Long-Term Outcome After Angioplasty for Symptomatic Extracranial Carotid Stenosis in Poor Surgical Candidates Stroke, December 1, 2002; 33(12): 2877 - 2880. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.J. Cunningham, R. Bond, Z. Mehta, M.R. Mayberg, C.P. Warlow, and P.M. Rothwell Long-Term Durability of Carotid Endarterectomy for Symptomatic Stenosis and Risk Factors for Late Postoperative Stroke Stroke, November 1, 2002; 33(11): 2658 - 2663. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. M. van Heesewijk, J. A. Vos, E. S. Louwerse, J. C. van den Berg, T. T. C. Overtoom, S. M. P. G. Ernst, H. W. Mauser, F. L. Moll, and R. G. A. Ackerstaff New Brain Lesions at MR Imaging after Carotid Angioplasty and Stent Placement Radiology, August 1, 2002; 224(2): 361 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. G. Nadareishvili, B. Bowyer, G. Cheung, D. W. Rowed, R. Maggisano, and J. W. Norris How Safe Is Carotid Angioplasty and Stenting in NASCET-Ineligible Patients? Stroke, November 1, 2001; 32(11): 2726 - 2726. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |